Profile
Yona Geffen worked as the Chief Executive Officer at Avraham Pharmaceuticals Ltd.
from 2011 to 2016.
Prior to that, Dr. Geffen held the position of Director-Executive Drug Development at BioLineRx Ltd.
and Vice President-Research & Development at Gamida Cell Ltd.
Dr. Geffen obtained graduate and doctorate degrees from Ben-Gurion University of the Negev.
Former positions of Yona Geffen
| Companies | Position | End |
|---|---|---|
Avraham Pharmaceuticals Ltd.
 Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Chief Executive Officer | 30/11/2016 |
| GAMIDA CELL LTD. | Chief Tech/Sci/R&D Officer | - |
| BIOLINERX LTD. | Corporate Officer/Principal | - |
Training of Yona Geffen
| Ben-Gurion University of the Negev | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| BIOLINERX LTD. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| Private companies | 1 |
|---|---|
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Health Technology |
- Stock Market
- Insiders
- Yona Geffen
